Tocilizumab for relapsing and remitting giant cell arteritis: a case series

Area of Science:

• Rheumatology
• Immunology
• Clinical Medicine

Background:

• Giant cell arteritis (GCA) is a large vessel vasculitis requiring high-dose corticosteroids.
• Corticosteroids are associated with significant long-term side effects.
• Tocilizumab offers a potential steroid-sparing treatment for refractory GCA.

Observation:

• A hub and spoke pathway for tocilizumab in GCA was established in 2018.
• 16 consecutive patients with refractory or relapsing GCA were included (August 2018 - April 2021).
• The pathway served a population of 1.3 million in the south of England.

Findings:

• Tocilizumab use led to a significant reduction in corticosteroid duration and dosage (mean prednisolone reduction 20.4 mg).
• 50% of patients continued tocilizumab beyond the initial 12-month funding period.
• The study details disease course, response patterns, and remission maintenance.

Implications:

• The hub and spoke model effectively reduces steroid burden in GCA patients.
• This pathway demonstrates the clinical utility of tocilizumab in managing GCA.
• Replication of this model in other centers could improve GCA patient outcomes.